Mural Oncology Net Worth
Mural Oncology Net Worth Breakdown | MURA |
Mural Oncology Net Worth Analysis
Mural Oncology's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mural Oncology's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mural Oncology's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mural Oncology's net worth analysis. One common approach is to calculate Mural Oncology's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mural Oncology's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mural Oncology's net worth. This approach calculates the present value of Mural Oncology's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mural Oncology's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mural Oncology's net worth. This involves comparing Mural Oncology's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mural Oncology's net worth relative to its peers.
Enterprise Value |
|
To determine if Mural Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mural Oncology's net worth research are outlined below:
| Mural Oncology plc had very high historical volatility over the last 90 days | |
| Mural Oncology plc has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (207.45 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mural Oncology generates negative cash flow from operations | |
| Mural Oncology plc has a frail financial position based on the latest SEC disclosures | |
| About 69.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
Mural Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mural Oncology plc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mural Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Follow Mural Oncology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 62.1 M.Market Cap |
|
Project Mural Oncology's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.72) | |
| Return On Capital Employed | (0.71) | (0.75) | |
| Return On Assets | (0.69) | (0.72) | |
| Return On Equity | (0.79) | (0.75) |
When accessing Mural Oncology's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mural Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mural Oncology's profitability and make more informed investment decisions.
Please note, the presentation of Mural Oncology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mural Oncology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Mural Oncology's management manipulating its earnings.
Evaluate Mural Oncology's management efficiency
Mural Oncology plc has return on total asset (ROA) of (0.8105) % which means that it has lost $0.8105 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7834) %, meaning that it created substantial loss on money invested by shareholders. Mural Oncology's management efficiency ratios could be used to measure how well Mural Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of December 17, 2024, Return On Tangible Assets is expected to decline to -0.72. In addition to that, Return On Capital Employed is expected to decline to -0.75. At present, Mural Oncology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 291.2 M, whereas Non Current Assets Total are forecasted to decline to about 22.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 15.81 | 16.60 | |
| Tangible Book Value Per Share | 15.81 | 16.60 | |
| Enterprise Value Over EBITDA | 0.81 | 0.86 | |
| Price Book Value Ratio | 0.37 | 0.39 | |
| Enterprise Value Multiple | 0.81 | 0.86 | |
| Price Fair Value | 0.37 | 0.39 | |
| Enterprise Value | -157 M | -149.2 M |
The strategic initiatives led by Mural Oncology's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Return On Equity (1.78) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mural Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mural Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mural Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Goodman Vicki L over a month ago Disposition of 5069 shares by Goodman Vicki L of Mural Oncology at 3.33 subject to Rule 16b-3 | ||
Minegishi Sachiyo over two months ago Insider Trading | ||
Altschuller Susan over three months ago Acquisition by Altschuller Susan of 10000 shares of Mural Oncology at 3.2071 subject to Rule 16b-3 | ||
Golumbeski George over three months ago Insider Trading | ||
Keson-brookes Maiken over three months ago Disposition of 2157 shares by Keson-brookes Maiken of Mural Oncology at 3.41 subject to Rule 16b-3 | ||
Caroline Loew over three months ago Disposition of 12531 shares by Caroline Loew of Mural Oncology at 2.91 subject to Rule 16b-3 | ||
Hickey Benjamin over six months ago Acquisition by Hickey Benjamin of 15021 shares of Mural Oncology at 3.61 subject to Rule 16b-3 | ||
Jackson Scott Thomas over six months ago Insider Trading | ||
Cafico Trust Co Ltd over a year ago Mural Oncology exotic insider transaction detected |
Mural Oncology Corporate Filings
| 14th of November 2024 Other Reports | ViewVerify | |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 8th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Mural Oncology Earnings per Share Projection vs Actual
Mural Oncology Corporate Executives
Elected by the shareholders, the Mural Oncology's board of directors comprises two types of representatives: Mural Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mural. The board's role is to monitor Mural Oncology's management team and ensure that shareholders' interests are well served. Mural Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mural Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
When determining whether Mural Oncology plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mural Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mural Oncology Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mural Oncology Plc Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mural Oncology plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mural Oncology. If investors know Mural will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mural Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.03) | Return On Assets (0.81) | Return On Equity (1.78) |
The market value of Mural Oncology plc is measured differently than its book value, which is the value of Mural that is recorded on the company's balance sheet. Investors also form their own opinion of Mural Oncology's value that differs from its market value or its book value, called intrinsic value, which is Mural Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mural Oncology's market value can be influenced by many factors that don't directly affect Mural Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mural Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mural Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mural Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.